Lung Cancer Diagnostics Market, by Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer), Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others): Global Opportunity Analysis and Industry Forecast, 2020-2027

The global lung cancer diagnostics market is estimated to surpass $4,074.0 million by 2027, exhibiting a CAGR of 8.1% from 2020 to 2027.

OFFERINGS OF THE REPORT:

The report offers comprehensive analysis of the global lung cancer diagnostics market by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market.

The report also sheds light on present scenario and upcoming trends and developments that are contributing in the growth of the market. In addition, key market boomers and opportunities driving the market growth are provided in the report. Besides, restraints and challenges that hold power to obstruct the market growth are also profiled in the report. The report also offers Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.

Based on the key forces molding the market, the report offers future perspective and growth outlook of the global market. The report offers market size and forecast by keenly evaluating every segment of the global lung cancer diagnostics market. Regional market breakdown of these segments is also offered in the report. The report divides the global lung cancer diagnostics market into four main regions including Europe, North America, Asia-Pacific, and LAMEA. Furthermore, these regions are sub-divided to profile detailed panorama of the lung cancer diagnostics market across major countries in specific regions. Moreover, the report reveals some of the recent developments, trends, and forthcoming opportunities in every region.

HIGHLIGHTS OF THE MARKET

• The report offers market size and forecast for the period from 2019 to 2027
• This report highlights trends, innovations, and new developments along with a detailed quantitative analysis of the lung cancer diagnostics market during the period of forecast
• The prevailing and upcoming opportunities along with the tactical assessment of the global lung cancer diagnostics market growth is provided
• The market size and estimations are based on a comprehensive analysis of market drivers and restraints and key innovations in the lung cancer diagnostics market
• Information on leading market players, Porter’s Five Analysis, and top winning business strategies is offered
• The development plans and initiatives undertaken by the top market players are highlighted to understand the competitive landscape of the market

KEY MARKET SEGMENTS

The report segments the global market into type ,test

• Type: Small Cell Lung Cancer, Non-small Cell Lung Cancer

• Test: Imaging Test, Biopsy, Sputum Cytology, Molecular Test, Others

Region:

The global lung cancer diagnostics market is divided into North America, Europe, Asia Pacific, and LAMEA.

The above-mentioned regions are further dived in countries as follows:

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

• LAMEA
  • Brazil
  • Argentina
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of LAMEA

LEADING PLAYERS OF THE MARKET

The most influential companies are mentioned in the report which include AstraZeneca, Qiagen N.V., Illumina Inc., Janssen and Sanofi S.A.

The report outlines the business overview including financial performance, latest strategic moves & developments, product portfolio, and SWOT analysis of the leading players of the lung cancer diagnostics market.

1. Roche Diagnostics

2. Thermo Fisher Scientific

3. Qiagen N.V.

4. Agilent Technologies

5. AstraZeneca

6. Janssen and Sanofi S.A.

7. bioM

• 1. RESEARCH METHODOLOGY

  • 1.1. Desk Research

  • 1.2. Real time insights and validation

  • 1.3. Forecast model

  • 1.4. Assumptions and forecast parameters

  • 1.5. Market size estimation

    • 1.5.1. Top-down approach

    • 1.5.2. Bottom-up approach

• 2. REPORT SCOPE

  • 2.1. Market definition

  • 2.2. Key objectives of the study

  • 2.3. Report overview

  • 2.4. Market segmentation

  • 2.5. Overview of the impact of COVID-19 on Global Lung Cancer Diagnostics Market

• 3. EXECUTIVE SUMMARY

• 4. MARKET OVERVIEW

  • 4.1. Introduction

  • 4.2. Growth impact forces

    • 4.2.1. Drivers

    • 4.2.2. Restraints

    • 4.2.3. Opportunities

  • 4.3. Market value chain analysis

    • 4.3.1. List of raw material suppliers

    • 4.3.2. List of manufacturers

    • 4.3.3. List of distributors

  • 4.4. Innovation & sustainability matrices

    • 4.4.1. Technology matrix

    • 4.4.2. Regulatory matrix

  • 4.5. Porter’s five forces analysis

    • 4.5.1. Bargaining power of suppliers

    • 4.5.2. Bargaining power of consumers

    • 4.5.3. Threat of substitutes

    • 4.5.4. Threat of new entrants

    • 4.5.5. Competitive rivalry intensity

  • 4.6. PESTLE analysis

    • 4.6.1. Political

    • 4.6.2. Economical

    • 4.6.3. Social

    • 4.6.4. Technological

    • 4.6.5. Environmental

  • 4.7. Impact of COVID-19 on Lung Cancer Diagnostics Market

    • 4.7.1. Pre-covid market scenario

    • 4.7.2. Post-covid market scenario

• 5. Lung Cancer Diagnostics Market, By Product

  • 5.1. Overview

  • 5.2 Small Cell Lung Cancer

    • 5.2.1 Definition, key trends, growth factors, and opportunities

    • 5.2.2 Market size analysis, by region, 2020-2027

    • 5.2.3 Market share analysis, by country, 2020-2027

  • 5.3 Non-small Cell Lung Cancer

    • 5.3.1 Definition, key trends, growth factors, and opportunities

    • 5.3.2 Market size analysis, by region, 2020-2027

    • 5.3.3 Market share analysis, by country, 2020-2027

  • 5.4 Research Dive Exclusive Insights

    • 5.4.1 Market attractiveness

    • 5.4.2 Competition heatmap

• 6. Lung Cancer Diagnostics Market, By Compounding Type

  • 6.1. Overview

  • 6.2 Imaging Test

    • 6.2.1 Definition, key trends, growth factors, and opportunities

    • 6.2.2 Market size analysis, by region, 2020-2027

    • 6.2.3 Market share analysis, by country, 2020-2027

  • 6.3 Biopsy

    • 6.3.1 Definition, key trends, growth factors, and opportunities

    • 6.3.2 Market size analysis, by region, 2020-2027

    • 6.3.3 Market share analysis, by country, 2020-2027

  • 6.4 Sputum Cytology

    • 6.4.1 Definition, key trends, growth factors, and opportunities

    • 6.4.2 Market size analysis, by region, 2020-2027

    • 6.4.3 Market share analysis, by country, 2020-2027

  • 6.5 Molecular Test

    • 6.5.1 Definition, key trends, growth factors, and opportunities

    • 6.5.2 Market size analysis, by region, 2020-2027

    • 6.5.3 Market share analysis, by country, 2020-2027

  • 6.6 Others

    • 6.6.1 Definition, key trends, growth factors, and opportunities

    • 6.6.2 Market size analysis, by region, 2020-2027

    • 6.6.3 Market share analysis, by country, 2020-2027

  • 6.7 Research Dive Exclusive Insights

    • 6.7.1 Market attractiveness

    • 6.7.2 Competition heatmap

• 7. Lung Cancer Diagnostics Market, By Region

  • 7.1 North America

    • 7.1.1 U.S

      • 7.1.1.1 Market size analysis, By Product, 2020-2027

      • 7.1.1.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.1.2 Canada

      • 7.1.2.1 Market size analysis, By Product, 2020-2027

      • 7.1.2.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.1.3 Mexico

      • 7.1.3.1 Market size analysis, By Product, 2020-2027

      • 7.1.3.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.1.4 Research Dive Exclusive Insights

      • 7.1.4.1 Market attractiveness

      • 7.1.4.2 Competition heatmap

  • 7.2 Europe

    • 7.2.1 Germany

      • 7.2.1.1 Market size analysis, By Product, 2020-2027

      • 7.2.1.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.2.2 UK

      • 7.2.2.1 Market size analysis, By Product, 2020-2027

      • 7.2.2.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.2.3 France

      • 7.2.3.1 Market size analysis, By Product, 2020-2027

      • 7.2.3.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.2.4 Spain

      • 7.2.4.1 Market size analysis, By Product, 2020-2027

      • 7.2.4.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.2.5 Italy

      • 7.2.5.1 Market size analysis, By Product, 2020-2027

      • 7.2.5.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.2.6 Rest of Europe

      • 7.2.6.1 Market size analysis, By Product, 2020-2027

      • 7.2.6.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.2.7 Research Dive Exclusive Insights

      • 7.2.7.1 Market attractiveness

      • 7.2.7.2 Competition heatmap

  • 7.3 Asia-Pacific

    • 7.3.1 China

      • 7.3.1.1 Market size analysis, By Product, 2020-2027

      • 7.3.1.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.3.2 Japan

      • 7.3.2.1 Market size analysis, By Product, 2020-2027

      • 7.3.2.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.3.3 India

      • 7.3.3.1 Market size analysis, By Product, 2020-2027

      • 7.3.3.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.3.4 Australia

      • 7.3.4.1 Market size analysis, By Product, 2020-2027

      • 7.3.4.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.3.5 South Korea

      • 7.3.5.1 Market size analysis, By Product, 2020-2027

      • 7.3.5.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.3.6 Rest of Asia-Pacific

      • 7.3.6.1 Market size analysis, By Product, 2020-2027

      • 7.3.6.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.3.7 Research Dive Exclusive Insights

      • 7.3.7.1 Market attractiveness

      • 7.3.7.2 Competition heatmap

  • 7.4 LAMEA

    • 7.4.1 Brazil

      • 7.4.1.1 Market size analysis, By Product, 2020-2027

      • 7.4.1.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.4.2 Saudi Arabia

      • 7.4.2.1 Market size analysis, By Product, 2020-2027

      • 7.4.2.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.4.3 UAE

      • 7.4.3.1 Market size analysis, By Product, 2020-2027

      • 7.4.3.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.4.4 South Africa

      • 7.4.4.1 Market size analysis, By Product, 2020-2027

      • 7.4.4.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.4.5 Rest of LAMEA

      • 7.4.5.1 Market size analysis, By Product, 2020-2027

      • 7.4.5.2 Market size analysis, By Compounding Type, 2020-2027

    • 7.4.6 Research Dive Exclusive Insights

      • 7.4.6.1 Market attractiveness

      • 7.4.6.2 Competition heatmap

• 8. Competitive Landscape

  • 8.1 Top winning strategies, 2020-2027

    • 8.1.1 By strategy

    • 8.1.2 By year

  • 8.2 Strategic overview

  • 8.3 Market share analysis, 2020-2027

• 9. Company Profiles

  • 9.1 Roche Diagnostics

    • 9.1.1 Overview

    • 9.1.2 Business segments

    • 9.1.3 Product portfolio

    • 9.1.4 Financial performance

    • 9.1.5 Recent developments

    • 9.1.6 SWOT analysis

  • 9.2 Thermo Fisher Scientific

    • 9.2.1 Overview

    • 9.2.2 Business segments

    • 9.2.3 Product portfolio

    • 9.2.4 Financial performance

    • 9.2.5 Recent developments

    • 9.2.6 SWOT analysis

  • 9.3 Qiagen N.V.

    • 9.3.1 Overview

    • 9.3.2 Business segments

    • 9.3.3 Product portfolio

    • 9.3.4 Financial performance

    • 9.3.5 Recent developments

    • 9.3.6 SWOT analysis

  • 9.4 Agilent Technologies

    • 9.4.1 Overview

    • 9.4.2 Business segments

    • 9.4.3 Product portfolio

    • 9.4.4 Financial performance

    • 9.4.5 Recent developments

    • 9.4.6 SWOT analysis

  • 9.5 AstraZeneca

    • 9.5.1 Overview

    • 9.5.2 Business segments

    • 9.5.3 Product portfolio

    • 9.5.4 Financial performance

    • 9.5.5 Recent developments

    • 9.5.6 SWOT analysis

  • 9.6 Janssen and Sanofi S.A.

    • 9.6.1 Overview

    • 9.6.2 Business segments

    • 9.6.3 Product portfolio

    • 9.6.4 Financial performance

    • 9.6.5 Recent developments

    • 9.6.6 SWOT analysis

  • 9.7 bioMérieux

    • 9.7.1 Overview

    • 9.7.2 Business segments

    • 9.7.3 Product portfolio

    • 9.7.4 Financial performance

    • 9.7.5 Recent developments

    • 9.7.6 SWOT analysis

  • 9.8 Illumina Inc.

    • 9.8.1 Overview

    • 9.8.2 Business segments

    • 9.8.3 Product portfolio

    • 9.8.4 Financial performance

    • 9.8.5 Recent developments

    • 9.8.6 SWOT analysis

  • 9.9 Janssen Pharmaceuticals, Inc.

    • 9.9.1 Overview

    • 9.9.2 Business segments

    • 9.9.3 Product portfolio

    • 9.9.4 Financial performance

    • 9.9.5 Recent developments

    • 9.9.6 SWOT analysis

  • 9.10 Company 10

    • 9.10.1 Overview

    • 9.10.2 Business segments

    • 9.10.3 Product portfolio

    • 9.10.4 Financial performance

    • 9.10.5 Recent developments

    • 9.10.6 SWOT analysis

* Taxes/Fees, If applicable will be added during checkout. All prices in USD.